Pharming Group N.V. (PHAR) announced a public cash offer to acquire all issued and outstanding shares of Abliva AB for SEK 0.45 per share in cash. The transaction is valued at approximately US$66.1 million.
The Board of Directors of Abliva recommended the shareholders of Abliva to accept the offer.
The acceptance period in the offer is expected to commence on or around January 16, 2025 and to expire on or around February 7, 2025.
Abliva's lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.